國家衛生研究院 NHRI:Item 3990099045/13112
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 861669      在线人数 : 671
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/13112


    题名: Effects of urate-lowering therapy on risk of hyperlipidemia in gout by a population-based cohort study and on in vitro hepatic lipogenesis-related gene expression
    作者: Fang, YJ;Wu, TY;Lin, CL;Su, CY;Li, JR;Chung, YL;Tien, N;Lim, YP
    贡献者: NHRI Graduate Student Program;National Institute of Environmental Health Sciences
    摘要: Patients with gout are at a higher risk of cardiovascular disease, which is associated with hyperlipidemia. Management of gout in Taiwan is poor, and the association between urate-lowering therapy (ULT) among gout patients and hyperlipidemia is unclear. We conducted a retrospective cohort study using data from the Longitudinal Health Insurance Database (LHID) of Taiwan on new-onset gout patients and a comparison cohort without gout. A Cox proportional hazards model was used to analyze differences in the risk of hyperlipidemia between patients with and without gout after considering related comorbidities. We also examined the ULT medications on the hepatic expression of lipogenesis-related genes. After adjusting for potential confounders, the case group (44,413 patients) was found to have a higher risk of hyperlipidemia than the control cohort (177,652 patients) [adjusted hazards ratio aHR=2.55]. Gout patients without antigout treatment had significantly higher risk of hyperlipidemia than the control cohort (aHR=3.10). Among gout patients receiving ULT, except those receiving probenecid (aHR=0.80), all had significantly lower risk of hyperlipidemia than gout patients without ULT (all aHR<0.90). Using real-time polymerase chain reaction, we found that most of the antigout drugs decreased the expression of hepatic genes related to lipogenesis in differentiated HepaRG cells. These data indicate that these antigout drugs reduce hyperlipidemia in gout patients, partly via the reduction in expression of lipogenesis-related genes, leading to improved blood lipid profiles. We provide evidence of the strong association between gout and hyperlipidemia and highlight the need for appropriate treatment guidelines.
    日期: 2020-11
    關聯: Mediators of Inflammation. 2020 Nov;2020:Article number 8890300.
    Link to: http://dx.doi.org/10.1155/2020/8890300
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0962-9351&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000595823800001
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85097058668
    显示于类别:[其他] 期刊論文
    [其他] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    ISI000595823800001.pdf933KbAdobe PDF229检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈